England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Executive Summary
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
You may also be interested in...
Keytruda: NICE Rejects English Funding For Endometrial Cancer But Says Yes For Renal Cancer
NICE has preliminarily rejected MSD’s drug for endometrial cancer in a decision that contrasts with that of its health technology assessment counterpart in Scotland.
Improved Discount Helps Lilly Secure English Funding For Verzenios
Verzenios is now the second CDK4/6 inhibitor for advanced breast cancer that can be used routinely on England’s National Health Service in patients in a second-line setting.
EPO Supports Early Unitary Patent Uptake From 1 January
The European Patent Office has adjusted the starting date of its transitional measures for applicants that want their patent to have unitary effect under the coming Unified Patent Court system.